within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AK01_Pyrazinamide;

model Pyrazinamide
  extends Pharmacolibrary.Drugs.ATC.J.J04AK01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J04AK01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pyrazinamide is a synthetic pyrazine analogue antitubercular agent used primarily for the treatment of active tuberculosis as part of combination therapy. It is included in standard first-line regimens recommended by the World Health Organization (WHO). It is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Abulfathi, AA, et al., &amp; Reuter, H (2019). Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. <i>Clinical pharmacokinetics</i> 58(9) 1103–1129. DOI:<a href=\"https://doi.org/10.1007/s40262-019-00764-2\">10.1007/s40262-019-00764-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31049868/\">https://pubmed.ncbi.nlm.nih.gov/31049868</a></p></li><li><p>Sullins, AK, &amp; Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatric drugs</i> 15(2) 93–117. DOI:<a href=\"https://doi.org/10.1007/s40272-013-0017-5\">10.1007/s40272-013-0017-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23529866/\">https://pubmed.ncbi.nlm.nih.gov/23529866</a></p></li><li><p>Tantalo, LC, et al., &amp; Mitjà, O (2023). Antimicrobial susceptibility of Treponema pallidum subspecies pallidum: an in-vitro study. <i>The Lancet. Microbe</i> 4(12) e994–e1004. DOI:<a href=\"https://doi.org/10.1016/S2666-5247(23)00219-7\">10.1016/S2666-5247(23)00219-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37827185/\">https://pubmed.ncbi.nlm.nih.gov/37827185</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Pyrazinamide;
